Biomark Diagnostics Inc
20B
Company Profile
Business description
Biomark Diagnostics Inc is developing its early-stage cancer diagnostic technology platform. It is cancer diagnostics technology platform leverages "Omics" and machine learning with a focus on how to detect and treat cancers. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Contact
10451 Shellbridge Way
Suite 145
RichmondBCV6X 2W8
CANSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar analysts’ take on the takeover for this undervalued industrial player.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 3.60 | -0.04% |
| CAC 40 | 8,143.41 | 78.39 | 0.97% |
| DAX 40 | 25,586.62 | 282.56 | 1.12% |
| Dow JONES (US) | 51,682.64 | 95.40 | -0.18% |
| FTSE 100 | 10,758.47 | 99.34 | 0.93% |
| HKSE | 25,042.71 | 291.93 | 1.18% |
| NASDAQ | 26,522.54 | 104.25 | 0.39% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.20 | 82.06 | 0.60% |
| S&P 500 | 7,650.50 | 12.74 | 0.17% |
| S&P/ASX 200 | 8,731.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,949.91 | 38.04 | 0.97% |